129 related articles for article (PubMed ID: 37325296)
1. Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy.
McNamara B; Bellone S; Demirkiran C; Max Philipp Hartwich T; Santin AD
Gynecol Oncol Rep; 2023 Aug; 48():101218. PubMed ID: 37325296
[TBL] [Abstract][Full Text] [Related]
2. Combination of pembrolizumab and lenvatinib is a potential treatment option for heavily pretreated recurrent and metastatic head and neck cancer.
Chen TH; Chang PM; Yang MH
J Chin Med Assoc; 2021 Apr; 84(4):361-367. PubMed ID: 33496513
[TBL] [Abstract][Full Text] [Related]
3. Combination lenvatinib plus pembrolizumab in the treatment of ovarian clear cell carcinoma: A case series.
Calo CA; Levine MD; Brown MD; O'Malley DM; Backes FJ
Gynecol Oncol Rep; 2023 Apr; 46():101171. PubMed ID: 37065539
[TBL] [Abstract][Full Text] [Related]
4. Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.
Dierks C; Seufert J; Aumann K; Ruf J; Klein C; Kiefer S; Rassner M; Boerries M; Zielke A; la Rosee P; Meyer PT; Kroiss M; Weißenberger C; Schumacher T; Metzger P; Weiss H; Smaxwil C; Laubner K; Duyster J; von Bubnoff N; Miething C; Thomusch O
Thyroid; 2021 Jul; 31(7):1076-1085. PubMed ID: 33509020
[No Abstract] [Full Text] [Related]
5. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
Makker V; Rasco D; Vogelzang NJ; Brose MS; Cohn AL; Mier J; Di Simone C; Hyman DM; Stepan DE; Dutcus CE; Schmidt EV; Guo M; Sachdev P; Shumaker R; Aghajanian C; Taylor M
Lancet Oncol; 2019 May; 20(5):711-718. PubMed ID: 30922731
[TBL] [Abstract][Full Text] [Related]
6. Esophagitis as a complication of the combination of lenvatinib and pembrolizumab for advanced endometrial cancer: A case report.
Fellouah M; Auclair MH; Fortin S; Berdugo J; de Guerké L
Gynecol Oncol Rep; 2023 Oct; 49():101235. PubMed ID: 37636497
[TBL] [Abstract][Full Text] [Related]
7. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
Lee CH; Shah AY; Rasco D; Rao A; Taylor MH; Di Simone C; Hsieh JJ; Pinto A; Shaffer DR; Girones Sarrio R; Cohn AL; Vogelzang NJ; Bilen MA; Gunnestad Ribe S; Goksel M; Tennøe ØK; Richards D; Sweis RF; Courtright J; Heinrich D; Jain S; Wu J; Schmidt EV; Perini RF; Kubiak P; Okpara CE; Smith AD; Motzer RJ
Lancet Oncol; 2021 Jul; 22(7):946-958. PubMed ID: 34143969
[TBL] [Abstract][Full Text] [Related]
8. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.
Choueiri TK; Eto M; Motzer R; De Giorgi U; Buchler T; Basappa NS; Méndez-Vidal MJ; Tjulandin S; Hoon Park S; Melichar B; Hutson T; Alemany C; McGregor B; Powles T; Grünwald V; Alekseev B; Rha SY; Kopyltsov E; Kapoor A; Alonso Gordoa T; Goh JC; Staehler M; Merchan JR; Xie R; Perini RF; Mody K; McKenzie J; Porta CG
Lancet Oncol; 2023 Mar; 24(3):228-238. PubMed ID: 36858721
[TBL] [Abstract][Full Text] [Related]
9. Case Report: Hypertriglyceridemia-Induced Pancreatitis after Lenvatinib and Pembrolizumab Use.
Sultan K; Khan Z; Saadat S
Case Rep Oncol; 2024; 17(1):311-316. PubMed ID: 38390453
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy.
McNamara B; Bellone S; Demirkiran C; Hartwich TMP; Santin AD
Gynecol Oncol Rep; 2023 Aug; 48():101219. PubMed ID: 37325293
[TBL] [Abstract][Full Text] [Related]
11. A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors.
Kitano S; Fujiwara Y; Shimizu T; Iwasa S; Yonemori K; Kondo S; Shimomura A; Koyama T; Ebata T; Ikezawa H; Hayata N; Minoshima Y; Miura T; Kubota T; Yamamoto N
Cancer Chemother Pharmacol; 2022 Dec; 90(6):523-529. PubMed ID: 36289094
[TBL] [Abstract][Full Text] [Related]
12. Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement.
Bellone S; Buza N; Choi J; Zammataro L; Gay L; Elvin J; Rimm DL; Liu Y; Ratner ES; Schwartz PE; Santin AD
Clin Cancer Res; 2018 Jul; 24(14):3282-3291. PubMed ID: 29351920
[No Abstract] [Full Text] [Related]
13. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.
Marth C; Tarnawski R; Tyulyandina A; Pignata S; Gilbert L; Kaen D; Rubio MJ; Frentzas S; Beiner M; Magallanes-Maciel M; Farrelly L; Choi CH; Berger R; Lee C; Vulsteke C; Hasegawa K; Braicu EI; Wu X; McKenzie J; Lee JJ; Makker V
Int J Gynecol Cancer; 2022 Jan; 32(1):93-100. PubMed ID: 34799418
[TBL] [Abstract][Full Text] [Related]
14. Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment.
Han C; Bellone S; Zammataro L; Schwartz PE; Santin AD
Gynecol Oncol Rep; 2018 Aug; 25():41-44. PubMed ID: 29946554
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 Expressing Recurrent Clear Cell Carcinoma of the Vulva with Durable Partial Response to Pembrolizumab: A Case Report.
Sachdeva M; Ngoi NYL; Lim D; Poon MLM; Thian YL; Lim YW; Lim SE; Tong P; Lum JHY; Ng J; Ilancheran A; Domingo EJ; Low JJH; Tan DSP
Onco Targets Ther; 2021; 14():3921-3928. PubMed ID: 34234460
[TBL] [Abstract][Full Text] [Related]
16. Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer.
Mimura K; Shimomura A; Gota T; Ando K; Kawamura Y; Taniyama T; Oishi H; Shimizu C
Gynecol Oncol Rep; 2022 Dec; 44():101084. PubMed ID: 36277029
[TBL] [Abstract][Full Text] [Related]
17. Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial.
Kawazoe A; Fukuoka S; Nakamura Y; Kuboki Y; Wakabayashi M; Nomura S; Mikamoto Y; Shima H; Fujishiro N; Higuchi T; Sato A; Kuwata T; Shitara K
Lancet Oncol; 2020 Aug; 21(8):1057-1065. PubMed ID: 32589866
[TBL] [Abstract][Full Text] [Related]
18. Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination.
Arance A; de la Cruz-Merino L; Petrella TM; Jamal R; Ny L; Carneiro A; Berrocal A; Márquez-Rodas I; Spreafico A; Atkinson V; Costa Svedman F; Mant A; Khattak MA; Mihalcioiu C; Jang S; Cowey CL; Smith AD; Hawk N; Chen K; Diede SJ; Krepler C; Long GV
J Clin Oncol; 2023 Jan; 41(1):75-85. PubMed ID: 35867951
[TBL] [Abstract][Full Text] [Related]
19. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
Motzer R; Alekseev B; Rha SY; Porta C; Eto M; Powles T; Grünwald V; Hutson TE; Kopyltsov E; Méndez-Vidal MJ; Kozlov V; Alyasova A; Hong SH; Kapoor A; Alonso Gordoa T; Merchan JR; Winquist E; Maroto P; Goh JC; Kim M; Gurney H; Patel V; Peer A; Procopio G; Takagi T; Melichar B; Rolland F; De Giorgi U; Wong S; Bedke J; Schmidinger M; Dutcus CE; Smith AD; Dutta L; Mody K; Perini RF; Xing D; Choueiri TK;
N Engl J Med; 2021 Apr; 384(14):1289-1300. PubMed ID: 33616314
[TBL] [Abstract][Full Text] [Related]
20. Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab.
Makker V; Taylor MH; Oaknin A; Casado Herraez A; Orlowski R; Dutta L; Ren M; Zale M; O'Malley DM
Oncologist; 2021 Sep; 26(9):e1599-e1608. PubMed ID: 34190370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
